Difference between revisions of "Pharmacy"

From Dog
 
(35 intermediate revisions by the same user not shown)
Line 172: Line 172:
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Sulfasalazine|5-aminosalicylic acid]]</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Sulfasalazine|5-aminosalicylic acid]]</font>
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Irritable bowel disease]]</font>
+
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[ulcerative colitis]]</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
Line 443: Line 443:
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Budesonide]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Budesonide]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Asthma]], [[Irritable bowel disease]]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Asthma]], [[ulcerative colitis]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 mg/dog</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 mg/dog</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
Line 642: Line 642:
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chlorambucil]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chlorambucil]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]], [[Irritable bowel disease]]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]], [[ulcerative colitis]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.5 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.5 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
Line 1,890: Line 1,890:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Imipenem Imipenem]-cilastin (Broad-spectrum 'Gorilla-cillin')</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Imipenem-cilastin </font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2-10 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2 - 10 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM or slow IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM or slow IV</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Imipramine Imipramine] </font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Imipramine </font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Behavioural modification, urinary incontinence</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Behavioural modification, urinary incontinence</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-5.0 mg/cat</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5 - 5.0 mg/cat</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Insulin]], [[glargine]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Insulin]], [[glargine]]</font>
Line 2,301: Line 2,301:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Metaproterenol]]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Metaproterenol</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Bronchodilation</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Bronchodilation</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.325 - 0.65 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.325 - 0.65 mg/kg</font>
Line 2,307: Line 2,307:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6 hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Metaraminol]]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Metaraminol</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vascular support during shock</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vascular support during shock</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.01 - 0.1 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.01 - 0.1 mg/kg</font>
Line 2,319: Line 2,319:
 
| width="20%" height="50" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
| width="20%" height="50" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methazolamide]]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methazolamide</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[glaucoma]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[glaucoma]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
Line 2,325: Line 2,325:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Methenamine hippurate]]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methicillin </font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Urinary antiseptic</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">250 mg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs (use with extreme caution)</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methicillin]] </font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methimazole]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hyperthyroidism]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs, followed by</font>
 
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methocarbamol]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methocarbamol]]</font>
Line 2,349: Line 2,337:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Methohexital]] </font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methohexital </font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anaesthesia induction</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anaesthesia induction</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5% solution: 11 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5% solution: 11 mg/kg</font>
Line 2,373: Line 2,361:
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methoxyflurane Methoxyflurane] </font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Methoxyflurane</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Inhalation anaesthesia</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Inhalation anaesthesia</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">Induction: 3%, Maintenance: 0.5-1.5%</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">Induction: 3%, Maintenance: 0.5-1.5%</font>
Line 2,379: Line 2,367:
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methscopolamine  Methscopolamine bromide]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methscopolamine bromide</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anti-emetic</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anti-emetic</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.3-1.0 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.3-1.0 mg/kg</font>
Line 2,410: Line 2,398:
 
|-
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Methylprednisolone acetate]]</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Methylprednisolone acetate]]</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Eosinophilic granuloma complex|sinophilic ulcers, linear granulomas]]</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10-40 mg/cat</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">SQ, IM, intralesional</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 2 weeks x 2 - 6 treatments</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Asthma]]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Asthma]]</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
Line 2,427: Line 2,409:
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 - 24 weeks</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 - 24 weeks</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methylprednisolone  Methylprednisolone sodium succinate]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Methyltestosterone</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Spinal trauma</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">15-30 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 2hrs, then q 6hrs for 2 days, then taper dose over 5 - 7 days</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pyrazole  4-Methylpyrazole]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antifreeze toxicity</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 2 days, then</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" |
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Methyltestosterone  Methyltestosterone]</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anabolic steroid</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anabolic steroid</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="34" align="left" valign="top" |
 
| width="20%" height="34" align="left" valign="top" |
Line 2,463: Line 2,421:
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 48hrs</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 48hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Metoclopramide  Metoclopramide]</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Metoclopramide]]</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Gastric motility disorders, antiemetic</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Gastric motility disorders, [[antiemetic]]</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.2-0.5 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.2 -0.5 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO, IM, SQ</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO, IM, SQ</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1.0-2.0 mg/kg</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1.0 - 2.0 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
Line 2,481: Line 2,439:
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8hrs, 30 mins before meals</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8hrs, 30 mins before meals</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" |
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Metoprolol]]</font>
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Dysautonomia|Feline dysautonomia]</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Atrial fibrillation, [[hypertrophic cardiomyopathy]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.3 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.05 - 3.0 mg/kg</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Metoprolol  Metoprolol] (ß<sub>1</sub>-agonist)</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Metronidazole]]</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Atrial fibrillation, [hypertrophiccardiomyopathy.htm  hypertrophic cardiomyopathy]</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Colitis, [[Coccidiosis]], anaerobic infections</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2-15 mg/cat</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10 - 25 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 7 - 14 days</font>
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
| width="22%" height="20" align="left" valign="top" |
+
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">12.5-25.0 mg/cat</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">50 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Metronidazole]]</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Colitis, [[Coccidiosis]], [[Tritrichomoniasis]], anaerobic infections</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10-25 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 7 - 14 days</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]]</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">50mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Metyrapone]]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Metyrapone</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Cushing's syndrome]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Cushing's syndrome]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">65 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">65 mg/kg</font>
Line 2,519: Line 2,465:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Mirtazepine]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Mirtazepine]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">3mg/cat</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.75 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 3days</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 3 days</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Misoprostol  Misoprostol] (synthetic PGE<sub>1</sub>)</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Misoprostol]]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Mucosal protectant</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Mucosal protectant</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">3-5 <span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">µg/kg</span></font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">3 - 5 µg/kg</span></font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs as required</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs as required</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Miconazole Miconazole]</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Miconazole cream</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Fungal infections]]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Fungal infections]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1-3 cm</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 - 3 cm</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">topically</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">topically</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 2 - 4 weeks</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 2 - 4 weeks</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [[Midazolam]]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Midazolam]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Preanaesthetic, sedation, </font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Preanaesthetic, sedation, </font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.06-0.22 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.06 - 0.22 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
Line 2,549: Line 2,495:
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Milbemycin oxime|Milbemax]]</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Milbemycin oxime|Milbemax]]</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Heartworm and intestinal worm prophylaxis</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Heartworm and intestinal worm prophylaxis</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.5-2.0 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.5 - 2.0 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">monthly</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">monthly</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Silymarin Milk thistle] (silymarin)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Silymarin]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Free radical scavenger</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Free radical scavenger</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50-250 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50 - 250 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Mineral oil</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Mineral oil</font>
Line 2,565: Line 2,511:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Minocycline  Minocycline] (tetracycline antibiotic)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Mithramycin</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5-15 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Mithramycin Mithramycin]</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypercalcaemia]], testicular cancer, malignancies</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypercalcaemia]], testicular cancer, malignancies</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25-0.50 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25 - 0.50 µg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs x 2</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs x 2</font>
 
|-
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Mitotane]] (o,p-DDD)</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Mitotane]] (o,p-DDD)</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Pituitary-dependant [[Cushing's syndrome|hyperadrenocorticism]]</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Pituitary-dependant [[hyperadrenocorticism]]</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">25 mg/kg</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">25 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 7 days (maintenance)</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 7 days (maintenance)</font>
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">75-100 mg/kg/week PO</font>
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Mitoxantrone]]</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Mitoxantrone]]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Anticancer chemotherapy</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Anticancer chemotherapy</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">6.0-6.5 mg/m<sup>2</sup></font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">6.0 - 6.5 mg/m<sup>2</sup></font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3-4 weeks x 4 - 6</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3 - 4 weeks x 4 - 6</font>
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Morphine]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Morphine]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antitussive, [[analgesia]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antitussive, [[analgesia]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05-0.1 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05 - 0.1 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">SQ, IM</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">SQ, IM</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6 hrs</font>
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Moxifloxacin]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Moxifloxacin]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">''[[Mycobacterium spp]]'', ''[[Bartonella henselae infection|Bartonella spp]]''</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">''[[Mycobacterium spp]]'', ''Bartonella spp]]''</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5.0 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5.0 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hours</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hours</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Mycobacterial cell wall extract</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Naloxone</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Immunostimulation</font>
+
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">stereotypic behaviour</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1.5 ml</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20 mg</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, deep IM</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs x 1</font>
+
| width="20%" height="20" align="left" valign="top" |
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Nadolol  Nadolol] (ß<sub>1/2</sub>- antagonist)</font>
+
| width="20%" height="20" align="left" valign="top" |
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypertension]]</font>
+
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Shock</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25-0.5 mg/kg</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2 mg/kg</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 1 hr</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nafcillin  Nafcillin] (ß-lactam antibiotic)</font>
+
| width="20%" height="20" align="left" valign="top" |
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Resistant staphylococcal infections</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nalbuphine  Nalbuphine hydrochloride] (synthetic opioid)</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.75-1.5 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nalorphine  Nalorphine]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Opioid antagonist</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Naloxone  Naloxone HCl]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">stereotypic behaviour</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20 mg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
 
| width="20%" height="20" align="left" valign="top" |
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Shock</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 1hr</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Opioid antagonist</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Opioid antagonist</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.01-0.04 mg/kg</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.01 - 0.04 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">to effect, repeat as needed</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">to effect, repeat as needed</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Naltrexone  Naltrexone] (Trexan)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nandrolone</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Behavioural problems, lick granuloma</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2.2 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nandrolone  Nandrolone decanoate]</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anaemia</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anaemia</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10-50 mg/cat</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.0 - 10 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">weekly</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">weekly</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Pimaricin|Natamycin]] (Pimaracin)</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[N-acetylcysteine]]</font>
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Ocular fungal infections</font>
+
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">see [[Acetylcysteine]]</font>
| width="18%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">topically</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3 - 8hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/N-acetylcysteine  N-acetylcysteine]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">see Acetylcysteine</font>
 
 
| width="18%" height="20" align="left" valign="top" |
 
| width="18%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Neodarbazine</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Neomycin]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">4.5-9.0 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Neomycin  Neomycin]</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">7 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">7 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV, SC</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV, SC</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs (nephrotoxic)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs (nephrotoxic)</font>
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Hepatic encephalopathy]]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Hepatic encephalopathy]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">10-20 mg/kg</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">10 - 20 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">per rectum</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">per rectum</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 
|-
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Neostigmine]]</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Neostigmine]]</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Diagnostic aid for [myasthenia%20gravis.htm  myasthenia gravis]</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Diagnostic aid for [[myasthenia gravis]]</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">20 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg with 0.04 mg/kg of atropine</font></span>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">20 µg/kg with 0.04 mg/kg of atropine</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
Line 2,709: Line 2,595:
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided doses</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided doses</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Niacin Niacin] (Niacinamide)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Niacin</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Hypertriglyceridemia</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Hypertriglyceridemia</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50-100 mg/day</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">50 - 100 mg/day</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" |
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Nitenpyram]]</font>
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Vacor toxicosis</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Fleas]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">500-1000 mg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 tab</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">stat, then</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">200 mg </font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 2 weeks</font>
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nikethamide  Nikethamide]</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Antidote for CNS-depressant drugs</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">7.8-31.2 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat, then as needed</font>
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Nitenpyram]]</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Fleas]]</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 tab</font>
 
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">daily as needed</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">daily as needed</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nitrofurantoin  Nitrofurantoin]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nitroglycerin 2% ointment</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Urinary tract infection</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-4.0 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Prophylactic dose</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nitroglycerin Nitroglycerin] 2% ointment</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vasodilator for pre-load reduction</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vasodilator for pre-load reduction</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1/8-1/4 inch (0.3-0.6cm)</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1/8 - 1/4 inch (0.3-0.6cm)</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">cutaneously</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">cutaneously</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Nitroprusside Nitroprusside] (vasodilator)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nitroprusside</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Acute [[Congestive heart failure|CHF]]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Acute [[Congestive heart failure]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-10 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-10 µg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 1 min</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 1 min</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Norepinephrine Norepinephrine] bitartrate</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Norepinephrine</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Positive ionotrope</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Positive ionotrope</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05-0.3 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05 - 0.3 µg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 1 min</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 1 min</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Nortriptyline  Nortriptyline] (tricyclic antidepressant - noradrenaline reuptake inhibitor)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Novobiocin</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Behaviour disorders</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-2.0 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Novobiocin Novobiocin]</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Nystatin]]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Nystatin</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">100,000 IU</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">100,000 IU</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Octreotide]] (Sandostatin)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Octreotide]] </font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chylothorax]], [[Acromegaly]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chylothorax]], [[Acromegaly]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 mg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 mg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Ofloxacin]] (fluoroquinolone)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Ofloxacin</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-10.0 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-10.0 mg/kg</font>
Line 2,799: Line 2,649:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Olsalazine  Olsalazine sodium]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Omeprazole]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Diarrhoea|Inflammatory bowel disease]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10-20mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Omega fatty acids</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">see Derm caps</font>
 
| width="18%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Omeprazole]] (Losec)</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Gastritis, gastric ulceration</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Gastritis, gastric ulceration</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/cat</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Ondansetron]] - 5-HT<sub>3</sub> receptor antagonists</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Ondansetron]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-1.0 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 - 1.0 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Orbifloxacin]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Orbifloxacin]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-7.5 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5 - 7.5 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Megestrol acetate|Ovarid]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Megestrol acetate|Ovarid]]</font>
Line 2,835: Line 2,673:
 
| width="20%" height="18" align="left" valign="top" |
 
| width="20%" height="18" align="left" valign="top" |
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxacillin  Oxacillin]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Oxymorphone</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">22-40 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxazepam  Oxazepam]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Appetite stimulant</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.0-2.5 mg/cat</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxtriphylline  Oxtriphylline]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">6 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 -12hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/cat</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxybutynin Oxybutynin] (anticholinergic)</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Detrusor hyperspasticity</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/cat</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxymetholone  Oxymetholone]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Anabolic agent</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Oxymorphone]]</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Preanaesthetic</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Preanaesthetic</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.2 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">with ACP or atropine</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">with ACP or atropine</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxytetracycline  Oxytetracycline]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Oxytocin]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Dystocia</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">55-82.5 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 - 1.0 IU/kg</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Bartonella henselae infection|Haemobartonella]]</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">20-40 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8hrs for 3 weeks</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Oxytocin  Oxytocin]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Acute metritis</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5-1.0 IU/kg</font>
 
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 2hrs for max of 3 doses</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 2 hrs for max of 3 doses</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Paclitaxel  Paclitaxel] (mitotic inhibitor)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Paclitaxel]] </font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
Line 2,901: Line 2,691:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">pre-treat for anaphylaxis</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">pre-treat for anaphylaxis</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pancreatin  Pancreatic enzymes]</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Pancuronium bromide</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Exocrine pancreatic insufficiency]]</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1-2 tablets, 1-2 teaspoons</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">20 mins prior to food, bid</font>
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Pancuronium  Pancuronium bromide]</font>
 
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Paralytic agent for controlled anaesthesia</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Paralytic agent for controlled anaesthesia</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.044-0.11 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.044 - 0.11 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV </font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV </font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Paregoric  Paregoric]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Atovaquone|Parvaquone]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antidiarrhoeal</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma spp|Toxoplasmosis]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.05-0.06 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 - 30 mg/kg</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Paromomycin  Paromomycin] (aminosidine)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[D-penicillamine]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Cryptosporidium spp]]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[chronic hepatitis]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">125-165 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 - 15 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 5 days</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Paroxetine  Paroxetine] (SSRI)</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Behaviour modification</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1.25-2.5 mg/cat</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Atovaquone  Parvaquone]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma|Toxoplasmosis]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10-30 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">D- [http://en.wikipedia.org/wiki/Penicillamine  penicillamine]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Progressive hepatitis</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Penicillin G</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Penicillin G</font>
Line 2,949: Line 2,715:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pentazocine Pentazocine]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Pentazocine</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.2-3.3 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.2 - 3.3 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, SQ</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 4 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pentobarbital  Pentobarbital]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pentobarbital]]</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">General anaesthesia</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[general anesthesia]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">25-30 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">25 - 30 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
Line 2,963: Line 2,729:
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Status epilepticus]]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Status epilepticus]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">5-15 mg/kg</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">5 - 15 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
Line 2,969: Line 2,735:
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Sedation</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Sedation</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2-4 mg/kg</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2 - 4 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Cartrophen|Pentosan polysuphate]]</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pentosan polysulfate]]</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Disease modifying agent, arthritis</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Disease modifying agent, arthritis</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">3 mg/kg</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">3 mg/kg</font>
Line 2,979: Line 2,745:
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 7 days</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 7 days</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pentoxifylline Pentoxifylline] (phosphodiesterase antagonist)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Pentoxifylline</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Dermatomyositis]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Dermatomyositis]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">100 mg/cat</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="34" align="left" valign="top" |
 
| width="20%" height="34" align="left" valign="top" |
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus|Autoimmune skin diseases]]</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus|Autoimmune skin diseases]]</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">10 - 15 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Periactin</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Appetite stimulant</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1-4 mg/cat</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Petrolatum  Petrolatum], white</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Laxative</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1-5 ml/cat</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Phenamidine isethionate</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Phenamidine isethionate</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Feline babesiosis|Babesiosis]]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">''[[Babesia spp]]''</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">7.5 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">7.5 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
Line 3,011: Line 2,765:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Phenobarbital]]</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Phenobarbital]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Status epilepticus]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Status epilepticus]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5-5 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.5 - 5 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO, IM, IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO, IM, IV</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phenoxybenzamine Phenoxybenzamine HCl] (a-adrenergic antagonist)</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Phenoxybenzamine]]</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Hypertension|Acute hypertension]] from [[Pheochromocytoma]]</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Hypertension]], [[pheochromocytoma]]</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Bladder physiology|Detrusor areflexia]]</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Bladder physiology|Detrusor areflexia]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.5-10 mg/cat</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5 - 2.0 mg/cat</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
Line 3,039: Line 2,793:
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phentolamine Phentolamine] (a-adrenergic antagonist)</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Phentolamine</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Hypertension]] from [[Pheochromocytoma]]</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[hypertension]] from [[pheochromocytoma]]</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.02-0.1 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.02 - 0.1 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phenylephrine Phenylephrine] (a-adrenergic agonist)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Phenylephrine</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vasopressor, decongestant, mydriatic</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Vasopressor, decongestant, mydriatic</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.15 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.15 mg/kg</font>
Line 3,051: Line 2,805:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">as needed</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">as needed</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial"> [http://en.wikipedia.org/wiki/Phenylpropanolamine Phenylpropanolamine]</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Phenylpropanolamine</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Urethral sphincter incompetence</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[incontinence]]</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1.5-2.0 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1.5 - 2.0 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phenytoin  Phenytoin]</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Phenytoin]]</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Seizures]], ventricular arrhythmias</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy|Seizures]], ventricular arrhythmias</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2-3 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">2 - 3 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Phosphate (K or Na)</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Phosphate (K or Na)</font>
Line 3,069: Line 2,823:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">over 6 hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">over 6 hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Physostigmine]] (Syrup)</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Physostigmine (Syrup)</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Myasthenia gravis]], [[Glaucoma]], magic-mushroom intoxication</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Myasthenia gravis]], [[Glaucoma]], magic-mushroom intoxication</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.25-5.0 mg/cat</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.25-5.0 mg/cat</font>
Line 3,075: Line 2,829:
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Physostigmine  Physostigmine] (0.5%)</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Phytomenadione</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Dysautonomia|Feline dysautonomia]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">apply 1/8 inch</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">topically</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Phytomenadione  Phytomenadione]</font>
 
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">See Vitamin K1</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">See Vitamin K1</font>
 
| width="18%" height="20" align="left" valign="top" |
 
| width="18%" height="20" align="left" valign="top" |
Line 3,087: Line 2,835:
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Pilocarpine  Pilocarpine] 1% ophthalmic</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Pilocarpine 1% ophthalmic</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Dysautonomia]], [[glaucoma]]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[glaucoma]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 drop</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">1 drop</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">topically</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">topically</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Pimaricin]] (Pimaracin)</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Pimaricin</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Ocular fungal infections</font>
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Ocular fungal infections</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 drop</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 drop</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">topically</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">topically</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3 - 8hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 3 - 8 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Piroxicam  Piroxicam] (NSAID, non-selective COX inhibitor)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Piroxicam</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]], [[Cancer|Neoplasia]]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]], [[Cancer|neoplasia]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.3 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.3 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 - 72hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 - 72 hrs</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Plicamycin]]</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">Plicamycin</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypercalcemia]], testicular cancer, malignancies</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypercalcemia]], testicular cancer, malignancies</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25 - 0.50 µg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.25 - 0.50 µg/kg</font>
Line 3,111: Line 2,859:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs x 2</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs x 2</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Polyethylene glycol]]</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Polyethylene glycol</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Lubricant, intestinal cathartic</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Lubricant, intestinal cathartic</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">25 ml/kg</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">25 ml/kg</font>
Line 3,166: Line 2,914:
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Potassium gluconate</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Potassium gluconate</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypokalemic polymyopathy]]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hypokalemia]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5-8 mEq/cat</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5-8 mEq/dog</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Potassium iodide</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Potassium iodide</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Sporotrichosis spp]], [http://en.wikipedia.org/wiki/Pythiosis  pythiosis]</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[fungal infections]]</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">30-100 mg/cat</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">6 - 20 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 10-14 days</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 10-14 days</font>
 
|-
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Potassium permanganate (1:2000)</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Potassium permanganate (1:2000)</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Strychnine toxicosis</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Strychnine]] toxicosis</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">5 ml/kg in gastric lavage</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">5 ml/kg in gastric lavage</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
Line 3,193: Line 2,941:
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">Apply light coating</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">Apply light coating</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pradofloxacin]] ([[Fluoroquinolones|Fluoroquinolone]])</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pradofloxacin]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Broad-spectrum antimicrobial</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Broad-spectrum antimicrobial</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 - 10 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 - 10 mg/kg</font>
Line 3,214: Line 2,962:
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">''[[Platynosomum spp]]'', ''[[Paragonimus spp]]''</font>
+
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">''[[Paragonimus spp]]''</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">25-30 mg/kg</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">25 - 30 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 5-10 days</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 5-10 days</font>
Line 3,226: Line 2,974:
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Feline lower urinary tract disease (FLUTD)|Urethral obstruction]]</font>
+
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Cystitis]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5-2.0 mg/cat (0.07mg/kg)</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.07 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Prednisolone]]</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Prednisolone]]</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Eosinophilic ulcers, plasma cell gingivitis</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">anti-inflammatory</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs (each evening)</font>
 
|-
 
| width="20%" height="34" align="left" valign="top" |
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Plasmacytic lymphocytic enteritis</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs, then taper dose weekly</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs (each evening)</font>
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Urethritis, persistent </font><font size="2" face="Arial">hematuria</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.5-5.0 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Anti-inflammatory</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2.2 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
Line 3,259: Line 2,989:
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" |
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Prednisolone]] acetate</font>
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Chronic therapy</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Addison's disease|Hypoadrenocorticism]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">2-4 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 mg/kg</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 48hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" |
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Prednisolone sodium phosphate</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus|Immune-mediated skin diseases]]</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Shock</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1.1-2.2 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 12hrs until remission, then taper</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6hrs</font>
 
|-
 
|-
| width="20%" height="20" align="left" valign="top" |
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Prednisolone sodium succinate</font>
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Allergy</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Allergic bronchitis, [[asthma]]</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Immunosuppression</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">3 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
| width="20%" height="34" align="left" valign="top" |
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">[[Lymphosarcoma]], myeloproliferative disorders</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">[[Multiple myeloma]]</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Prednisolone]] acetate</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Addison's disease|Hypoadrenocorticism]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Prednisolone sodium phosphate</font>
 
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Shock</font>
 
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Prednisolone sodium succinate</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Allergic bronchitis, [[asthma]]</font>
 
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">15-30 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">15-30 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM</font>
Line 3,339: Line 3,033:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5ml q 24hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5ml q 24hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Primaquine]]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Procainamide</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Feline babesiosis]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Procainamide]]</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Ventricular arrhythmias</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Ventricular arrhythmias</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">62.5 mg/dog</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">62.5 mg/dog</font>
Line 3,351: Line 3,039:
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Prochlorperazine Prochlorperazine]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Prochlorperazine</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
+
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Antiemetic]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.1 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IM</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 +
|-
 +
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Promazine hydrochloride</font>
 +
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Pre-anaesthetic]]</font>
 +
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.2 - 6.6 mg/kg</font>
 +
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 +
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
| width="22%" height="20" align="left" valign="top" |
+
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Promazine  Promazine hydrochloride]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Preanaesthetic</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">2.2-6.6 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Antiemetic</font>
 
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6hrs</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 4 - 6hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Promethazine Promethazine] HCl</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Promethazine HCl</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antihistamine, antiemetic</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Antihistamine, antiemetic</font>
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.2-0.4 mg/kg</font>
+
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">0.2 - 0.4 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">IV, IM, PO</font>
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8 hrs</font>
 
|-
 
|-
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Propantheline_bromide  Propantheline bromide]</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">Propantheline bromide</font>
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Acute colitis, irritable bowel syndrome, antiemetic</font>
+
| width="22%" height="34" align="left" valign="top" | <font size="2" face="Arial">Acute [[colitis]], [[ulcerative colitis]], [[antiemetic]]</font>
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.22-0.25 mg/kg</font>
+
| width="18%" height="34" align="left" valign="top" | <font size="2" face="Arial">0.22 - 0.25 mg/kg</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8hrs up to 3 days</font>
+
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs up to 3 days</font>
 
|-
 
|-
 
| width="20%" height="34" align="left" valign="top" |
 
| width="20%" height="34" align="left" valign="top" |
Line 3,459: Line 3,141:
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 
| width="20%" height="34" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Propylthiouracil]] (PTU)</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Propylthiouracil (PTU)</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hyperthyroidism]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Hyperthyroidism]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
Line 3,467: Line 3,149:
 
| width="20%" height="20" align="left" valign="top" |
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" |
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">50 mg/cat</font>
+
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
Line 3,543: Line 3,225:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 14 - 28 days</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 14 - 28 days</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Quinacrine]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Quinacrine</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Giardia spp]], [[Coccidiosis]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Giardia spp]]'', [[Coccidiosis]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">11 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">11 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 5 days</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 5 days</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial"> [[Ranitidine]] (Zantac)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial"> [[Ranitidine]]</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">H-2 receptor antagonist for use in gastritis, GI tract ulceration</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[gastritis]], GI tract ulceration</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV, PO, SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV, PO, SQ</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypergastrinemia associated with chronic renal insufficiency</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">3.5 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Retinol] (Vit A)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Retinol]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Dermatological lesions</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Dermatological lesions</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">625 - 800 IU/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">625 - 800 IU/kg</font>
Line 3,587: Line 3,263:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">(warning: low therapeutic margin)</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">(warning: low therapeutic margin)</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 14 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs for 14 days</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Roxithromycin Roxithromycin]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Roxithromycin</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
Line 3,603: Line 3,279:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Selegiline]] (Fitergol)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Selegiline]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Cognitive disorders]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Cognitive disorders]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Cushing's syndrome|Hyperadrenocorticism]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[hyperadrenocorticism]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Selamectin]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Selamectin]]</font>
Line 3,645: Line 3,321:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfadiazine]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfadiazine</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Burns</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Burns</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">Apply light coating</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">Apply light coating</font>
Line 3,711: Line 3,387:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sorafenib]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sorafenib</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Chemotherapy]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 mg/kg</font>
Line 3,723: Line 3,399:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sotalol]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sotalol</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Ventricular arrhythmias</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Ventricular arrhythmias</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
Line 3,729: Line 3,405:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Spectinomycin]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spectinomycin</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-12 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-12 mg/kg</font>
Line 3,735: Line 3,411:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Spiramycin]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spiramycin</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma|Toxoplasmosis]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Toxoplasma spp]]''</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5-23 mg/cat</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5 - 23 mg/dog</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Spironolactone]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spironolactone</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Diuretic: heart failure</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Diuretic: heart failure</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2-4 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2-4 mg/kg</font>
Line 3,755: Line 3,431:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hepatic insufficiency</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hepatic insufficiency</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5 mg/cat</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">3.0 - 4.0 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Spironolactone]] / hydrochlorothiazide</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spironolactone / hydrochlorothiazide</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Diuretic, antihypertensive agent</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Diuretic]], antihypertensive agent</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12-24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Stanozolol]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Stanozolol]]</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anabolic agent, </font><font size="2" face="Arial">anaemia</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anabolic agent, [[anemia]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/dog</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/dog</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
Line 3,773: Line 3,449:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-25 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 25 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7days</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7days</font>
Line 3,779: Line 3,455:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Staphage lysate</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Staphage lysate</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Immune stimulant</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Immune stimulant</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 ml/cat</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.2 ml/cat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">then</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">then</font>
Line 3,795: Line 3,471:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">weekly for 10 - 12 weeks</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">weekly for 10 - 12 weeks</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Staphylococcal infections|Staphylococcal A]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Staphylococcus spp|Staphylococcal A]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Immune stimulant</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Immune stimulant</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/2.75kg</font></span>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 µg/2.75kg</font></span>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IP</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IP</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 3 - 5 days</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 3 - 5 days</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Streptomycin]], dihydro</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Streptomycin, dihydro</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Leptospirosis]], endocarditis, ''[[Mycobacterium spp]]'', ''[[Yersinia pestis]]''</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Leptospirosis]], [[endocarditis]], ''[[Mycobacterium spp]]'', ''[[Yersinia pestis]]''</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q6hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 6 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Succinylcholine Succinylcholine]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Succinylcholine</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Paralysis</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Paralysis</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.06-0.11 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.06 - 0.11 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sucralfate]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sucralfate</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Gastrointestinal ulceration</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Gastrointestinal ulceration</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250-500 mg/cat</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250-500 mg/cat</font>
Line 3,823: Line 3,499:
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">40 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">40 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfadiazine]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfadiazine</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Nocardiosis</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Nocardiosis</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">220 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">220 mg/kg</font>
Line 3,835: Line 3,511:
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">50-110 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">50-110 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma|Toxoplasmosis]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toxoplasma spp|Toxoplasmosis]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15-50 mg/kg (with pyrimethamine)</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 - 50 mg/kg (with pyrimethamine)</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided, for 14 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs, divided, for 14 days</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Trimethoprim/Sulphonamides]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Trimethoprim/Sulphonamides]]</font>
Line 3,850: Line 3,526:
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Meningitis</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Meningitis]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IV</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Nocardiosis</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Nocardiosis</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30-60 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 - 60 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, SQ</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfadimethoxine]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfadimethoxine</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">25-50 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">25 - 50 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM, IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM, IV</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs for max of 21days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs for max of 21 days</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
Line 3,879: Line 3,555:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfamethazine]], sulfamerazine</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfamethazine, sulfamerazine</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Coccidiosis]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Coccidiosis]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">200 mg/kg (loading), then 50 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">200 mg/kg (loading), then 50 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfamethoxazole]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfamethoxazole</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">100 mg/kg (loading), then 50 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">100 mg/kg (loading), then 50 mg/kg</font>
Line 3,891: Line 3,567:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfamethoxazole]]/[[Trimethoprim]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfamethoxazole/Trimethoprim</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
Line 3,898: Line 3,574:
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfasalazine]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Sulfasalazine]]</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[irritable bowel disease|Lymphocytic plasmacytic enteritis]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[ulcerative colitis]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250 mg/cat</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250 mg/cat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
Line 3,904: Line 3,580:
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Irritable bowel disease]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[ulcerative colitis]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20-25 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20-25 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 -24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 -24 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
Line 3,915: Line 3,591:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Sulfisoxazole Sulfisoxazole]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfisoxazole</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Urinary tract infections</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[cystitis]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">50 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">50 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfobromophthalein sodium</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Sulfobromophthalein sodium</font>
Line 3,927: Line 3,603:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">collect serum 30 min after BSP injection</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">collect serum 30 min after BSP injection</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Suprofen  Suprofen ophthalmic]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Suprofen ophthalmic</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Allergic conjunctivitis</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Allergic [[conjunctivitis]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1%</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1%</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tacrolimus]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tacrolimus]]</font>
Line 3,939: Line 3,615:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Taurine</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Telazol</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Taurine deficiency]], [[Cardiomyopathy - dilated|dilated cardiomyopathy]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250-500 mg/cat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Central retinal degeneration</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">250 mg/cat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Telazol (Zoletil - Tiletamine / zolazepam)</font>
 
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Restraint</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Restraint</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">6.6 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">6.6 mg/kg</font>
Line 3,958: Line 3,622:
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anaesthesia</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Anesthesia]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">11-15 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">11 - 15 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Temaril-P (Trimeprazine and prednisolone)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Terbinafine]]</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Allergy</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.7-1.1 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Lamisil|Terbinafine]] (Lamasil)</font>
 
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Fungal infections]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Fungal infections]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 - 30 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 - 30 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 4 - 10 wks</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 4 - 10 wks</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Terbutaline sulphate]] ([[adrenergic antagonists|ß<sub>2</sub>-adrenoceptor agonist]])</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Terbutaline]] sulphate</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ, IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ, IM</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 4hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 4 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1.25-2.5 mg/cat</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1.25 - 2.5 mg/cat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs</font>
Line 3,993: Line 3,651:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 2 - 3 days</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 2 - 3 days</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Testosterone, methyl</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Testosterone]], methyl</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anabolic effects</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anabolic effects</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg; max 30 mg/day</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg; max 30 mg/day</font>
Line 4,006: Line 3,664:
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Urinary incontinence</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[incontinence]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-10 mg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5 - 10 mg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
Line 4,013: Line 3,671:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5-1.0 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 - 1.0 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 2 - 3 days</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 2 - 3 days</font>
Line 4,023: Line 3,681:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">watch for anaphylaxis for 30 min</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">watch for anaphylaxis for 30 min</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tetracycline]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tetracycline</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Acute bronchitis</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Acute bronchitis</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-25 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 25 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12krs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Rickettsia spp]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Rickettsia spp]]''</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8hrs for 21 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 hrs for 21 days</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
Line 4,043: Line 3,701:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-5 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 5 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV, IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV, IM</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Methylxanthines|Theophylline]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Theophylline</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Theo-Dur (Sustained release)</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Theo-Dur (Sustained release)</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bronchodilator</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20-25 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 - 25 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, at night</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs, at night</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Thiabendazole Thiabendazole]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiabendazole</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Heartworm disease]] adulticide</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Heartworm disease]] adulticide</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">35 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">35 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 20 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs for 20 days</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Strongyloides</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Strongyloides spp]]''</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">125 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">125 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 3 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 3 days</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiacetarsamide</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiacetarsamide</font>
Line 4,075: Line 3,733:
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2.2 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2.2 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 2 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs for 2 days</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiamine (Vit B12)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiamine</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thiamine deficiency]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thiamine deficiency]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/cat</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/dog</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs until regression of symptoms</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs until regression of symptoms</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">100-250 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">100 - 250 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiamylal sodium</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thiamylal sodium</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anaesthesia</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anaesthesia</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">8.8-13.3 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">8.8 - 13.3 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">after tranquilisation</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">after tranquilisation</font>
Line 4,102: Line 3,760:
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thyroid</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thyroid</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypothyroidism</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Hypothyroidism]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15-20 mg/kg/day</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15 - 20 mg/kg/day</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thiopentone]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thiopentone]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">General anaesthesia, [[status epilepticus]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">General anaesthesia, [[status epilepticus]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">3-15 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">3 - 15 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">to effect</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Thyrotropin Thyrotropin] (TSH)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Thyrotropin</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Provocative testing</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Provocative testing</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 IU/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 IU/kg</font>
Line 4,120: Line 3,778:
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Acanthosis nigrans, hypothyroidism</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Acanthosis nigrans]], [[hypothyroidism]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 IU</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 IU</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 5 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs for 5 days</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">L-Thyroxine (levothyroxine)</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">L-Thyroxine (levothyroxine)</font>
Line 4,133: Line 3,791:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20-30 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">20 - 30 µg/kg</font></span>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Ticarcillin Ticarcillin]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Ticarcillin</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">33-50 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">33 - 50 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8kg</font>
Line 4,157: Line 3,815:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tiletamine / zolazepam</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tiletamine / zolazepam</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Minor procedure</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Minor procedure</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">9.7-11.9 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">9.7 - 11.9 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
Line 4,163: Line 3,821:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Castration</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Castration</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10.6-12.5 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10.6 - 12.5 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">do not exceed 72mg/kg with repeat doses</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">do not exceed 72 mg/kg with repeat doses</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spey</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Spey</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">14.3-15.8 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">14.3 - 15.8 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tinidazole]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]], ''[[Giardia spp]]''</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 14 days</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Tiopronin Tiopronin]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Cystine urinary calculi</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">15-20 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tolazoline</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tolazoline</font>
Line 4,191: Line 3,837:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tolfenamic acid]] (Tolfedine)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tolfenamic acid]] </font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Analgesia]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
Line 4,199: Line 3,845:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toltrazuril]] (Baycox)</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Toltrazuril]] (Baycox)</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Coccidiosis]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Coccidiosis]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-20 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5 - 20 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs x 2-5 treatments</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs x 2 - 5 treatments</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Toluene Toluene]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Toluene</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anthelmintic</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Anthelmintic</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">267 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">267 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">repeat in 2-4 weeks</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">repeat in 2 - 4 weeks</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tramadol]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Tramadol]]</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Opioids|Opioid]] [[analgesia]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Opioid [[analgesia]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5 mg/cat</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">12.5 mg/dog</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tretinoin</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Acne]], nasal hyperkeratosis</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.25-0.5 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs for 7 days</font>
 
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Triamcinolone]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Triamcinolone]]</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]], pododermatitis</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Gingivitis]], [[pododermatitis]], [[acral lick granuloma]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2-4 mg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 - 4 mg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Hypokalemic polymyopathy]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Pannus, [[episcleritis]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5-1.0 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antiinflammatory</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.11-0.22 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Pannus, eosinophilic keratitis, episcleritis</font>
 
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Subconjunctival</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Subconjunctival</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" |
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Triamterene</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Esophageal stricture</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/cat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">submucosal</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Glucocorticoid effect</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1-0.2 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Triamterene  Triamterene]</font>
 
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Diuretic</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Diuretic</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-2 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 2 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Trientine hydrochloride</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Trientine hydrochloride</font>
Line 4,273: Line 3,889:
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Triethylene thiophosphoramide</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Bladder neoplasia</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">30 mg/m<sup>2</sup></font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Intravesicular</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 3 - 4wks</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Thiethylperazine  Thiethylperazine]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antipsychotic</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.13-0.2 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Trifluoperazine  Trifluoperazine]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antipsychotic</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.03 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Triflupromazine  Triflupromazine]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Triflupromazine  Triflupromazine]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Behaviour modification</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Behaviour modification</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1-0.3 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.3 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Trifluridine  Trifluridine ophthalmic]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[FHV|herpes infection]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1% soln, 1-2 drops</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 34 - 8hrs</font>
 
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Triiodothyronine  Triiodothyronine] (T3)</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Triiodothyronine  Triiodothyronine] (T3)</font>
Line 4,323: Line 3,915:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Tripelennamine Tripelennamine]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Tripelennamine</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antihistamine</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antihistamine</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO, IM</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Trypan_blue  Trypan blue]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Trypan blue</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Feline babesiosis]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">''[[Babesia spp]]''</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
Line 4,353: Line 3,945:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Urokinase]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Urokinase</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Aortic thromboembolism]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[thromboembolism]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">90,000 IU over 20 minutes, then 45,000 IU CRI</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">90,000 IU over 20 minutes, then 45,000 IU CRI</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">for up to 24 hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">for up to 24 hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Urofollitropin Urofollitropin]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Urofollitropin</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypogonadotropic anovulation</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypogonadotropic anovulation</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 mg/cat</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 mg/dog</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Ursodeoxycholic acid]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Ursodeoxycholic acid]]</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Feline inflammatory liver disease|Chronic hepatitis]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[chronic hepatitis]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-15 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-15 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Valproic_acid  Valproic acid]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Valproic acid</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">25-65 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">25 - 65 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">with </font><font size="2" face="Arial">Phenobarbital</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">with </font><font size="2" face="Arial">[[Phenobarbital]]</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
Line 4,407: Line 3,999:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">over 30 min</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">over 30 min</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Verapamil]] (calcium channel blocker)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Verapamil]] </font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Supraventricular arrhythmias</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Supraventricular arrhythmias</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-15 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 15 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs, divided</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
Line 4,418: Line 4,010:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12hrs</font>
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Vidarabine]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Ocular herpesviral infection</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1/8 inch</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Topically</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 6 - 8hrs</font>
 
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Vinblastine]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Vinblastine]]</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Mast cell tumour]], [lymphosarcoma.htm  LSA]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Mast cell tumour]], [[lymphoma]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1-0.4 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.1 - 0.4 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q7-14 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7 - 14 days</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Vincristine]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Vincristine]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thrombocytopenia]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Thrombocytopenia]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01-0.025 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01 - 0.025 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7-10 days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7 - 10 days</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
Line 4,445: Line 4,031:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Neoplasia</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Neoplasia</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5-0.75 mg/m<sup>2</sup></font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.5 - 0.75 mg/m<sup>2</sup></font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IV</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7 - 14days</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 7 - 14 days</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Viokase]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Viokase</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Exocrine pancreatic insufficiency]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Exocrine pancreatic insufficiency]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">325 mg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">325 mg</font>
Line 4,485: Line 4,071:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D (dihydrotachysterol)</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypocalcemia</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypocalcemia</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.02 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.02 mg/kg</font>
Line 4,495: Line 4,081:
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01 mg/kg</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.01 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D2 (ergocalciferol)</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D2 (ergocalciferol)</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypocalcemia</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypocalcemia</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4000-6000 U/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">4000 - 6000 U/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, initially, then</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs, initially, then</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">500-1000 U/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">500 - 1000 U/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D3 (calcitriol - 1-25, dihydroxy vitamin D3)</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin D3 (calcitriol - 1-25, dihydroxy vitamin D3)</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Hypocalcemia</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Hypocalcemia]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.03-0.06 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.03-0.06 µg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Chronic renal disease]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Chronic renal disease]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.025 </font><span style="mso-fareast-font-family: Times New Roman; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><font size="2" face="Arial">µg/kg</font></span>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.025 µg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin E</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin E</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin E deficient myositis, [yellow%20fat%20disease.htm  steatitis]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[myopathy]], [[myocarditis]], [[retinal pigment epithelial dystrophy]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10-20 IU/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">10 - 20 IU/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus|autoimmune skin diseases]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Pemphigus]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">400-600 IU/cat</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">400 - 600 IU/dog</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin K1</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Vitamin K1</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Deficiency, hepatopathy</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Deficiency, hepatopathy</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1-3mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1 - 3mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ, PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ, PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12hrs for 4 - 6 weeks</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 hrs for 4 - 6 weeks</font>
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
Line 4,545: Line 4,131:
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided doses</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs, divided doses</font>
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Voriconazole]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Warfarin</font>
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Aspergillosis]]</font>
+
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[thromboembolism]]</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.06 - 0.20 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs. May cause neurotoxicity</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs. Maintain PTT at 2 - 2.5 times normal</font>
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[http://en.wikipedia.org/wiki/Warfarin  Warfarin]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Aortic thromboembolism]]</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.06-0.20 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24hrs. Maintain PTT at 2 - 2.5 times normal</font>
 
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Xylazine]]</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Xylazine]]</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Muscle relaxation</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Muscle relaxation</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1.1-2.2mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">1.1 - 2.2mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">IM, SQ</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">stat</font>
Line 4,569: Line 4,149:
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
|-
 
|-
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Zafirlukast]]</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Zafirlukast</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Leukotriene receptor antagonist</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Leukotriene receptor antagonist</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.15-0.2mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">0.15 - 0.2mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24hrs</font>
+
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 12 - 24 hrs</font>
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">[[Zidovudine]] (AZT)</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antiviral</font>
 
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">5-20 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">SQ, PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 8 - 12 hrs</font>
 
 
|-
 
|-
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Zinc</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">Zinc</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antioxidant</font>
 
| width="22%" height="10" align="left" valign="top" | <font size="2" face="Arial">Antioxidant</font>
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2-3 mg/kg</font>
+
| width="18%" height="10" align="left" valign="top" | <font size="2" face="Arial">2 - 3 mg/kg</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
| width="20%" height="10" align="left" valign="top" | <font size="2" face="Arial">q 24 hrs</font>
 
|-
 
|-
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Azithromycin|Zithromax]] (Azithromycin)]</font>
+
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">Zonisamide</font>
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">q 24 - 48 hrs</font>
 
|-
 
| width="20%" height="20" align="left" valign="top" |
 
| width="22%" height="20" align="left" valign="top" | <font size="2" face="Arial">Susceptible infections</font>
 
| width="18%" height="20" align="left" valign="top" | <font size="2" face="Arial">80 mg stat</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">PO</font>
 
| width="20%" height="20" align="left" valign="top" | <font size="2" face="Arial">weekly x 3</font>
 
|-
 
| width="20%" height="10" align="left" valign="top" |
 
| width="22%" height="10" align="left" valign="top" |
 
| width="18%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
| width="20%" height="10" align="left" valign="top" |
 
|-
 
| width="20%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Zonisamide]]</font>
 
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy]]</font>
 
| width="22%" height="18" align="left" valign="top" | <font size="2" face="Arial">[[Epilepsy]]</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>
 
| width="18%" height="18" align="left" valign="top" | <font size="2" face="Arial">5 mg/kg</font>

Latest revision as of 05:55, 29 April 2013

Below are listed some of the common drugs used in canine medicine. See the FDA Green book for a comprehensive list of approved veterinary medicines.

Drug

Indications Dose Route Frequency
Acarbose Diabetes mellitus 12.5 - 20 mg Oral with each meal
Acemannan Immunomodulation 1 - 2 mg/kg Intralesional, IP or SQ weekly
Acepromazine Sedation, restraint 0.05 - 2.25 mg/kg SQ, IM, PO q 8 - 12hrs
Aortic thromboembolism 0.15 - 0.3 mg/kg SQ q 8 - 12hrs
Amphetamine and pseudoephedrine toxicosis 0.05 -1.0 mg/kg IV, IM, SQ q 8 - 12hrs
Acetazolamide Glaucoma 5 - 10 mg/kg PO q 8 - 12hrs
Acetylcysteine Mucolytic (Asthma), Acetaminophen toxicity 140 mg/kg IV loading dose
5 - 10 mg/kg PO every 12 hours
Acetylsalicylic acid Antipyretic 6 - 10 mg/kg PO q 48 - 72hrs
Antithrombotic 25 mg/kg PO 2 times/wk
Anti-inflammatory 10 - 20 mg/kg PO q 48 hrs
Analgesia 10 mg/kg PO q 48hrs
Actinomycin D Chemotherapy / antimicrobial 0.5 - 0.9 mg/m2 IV once every 3 weeks
S-Adenosylmethionine Glutathione replenisher - chronic hepatitis, hepatic encephalopathy, portosystemic shunt 20 - 30 mg/kg PO q 24hrs
Aglepristone Mesalliance 10mg/kg SQ stat
Albendazole Lungworm 50 mg/kg PO daily for 21 days
Albuterol sulphate Bronchodilation 90 µg metered dose inhaler q 6 - 8hrs
Alfaxan general anesthesia 1 - 2 mL per 5 kg bodyweight IV bolus or slowly IV
Allopurinol Urate uroliths 10 mg/kg PO q 8 - 12hrs for 30 days
Alprazolam Anxiolytic 0.125 - 0.25 mg/dog PO q 12hrs
Aluminium carbonate gel Phosphate binder 10 - 30 mg/kg PO with meals q 8hrs
Aluminium hydroxide Antacid 20 - 30 ml PO q 2 - 4 hrs
Phosphate binder 30 - 90 mg/kg PO with meals q 8 - 24 hrs
Amantadine Analgesia for chronic pain 3 - 5 mg/kg PO daily for 7 - 14 days
Amikacin Susceptible infections 15 - 22 mg/kg IM, IV, SQ q 24hrs
Aminophylline Asthma 4 - 6.6 mg/kg PO q 8 - 12hrs
2 - 5 mg/kg IV infusion q 12hrs
5-aminosalicylic acid ulcerative colitis 20 mg/kg PO q 24 hrs
Amitriptyline (Endep-10) Analgesia 2 mg/kg PO q 24 hrs
Amlodipine besylate Systemic hypertension 0.625 mg PO q 24 hrs
Ammonium chloride Struvite dissolution 800 mg PO q 24 hrs
Amoxicillin/clavulanate Susceptible infections 10 - 20 mg/kg PO q 12 hrs
Amoxil Susceptible infections 4 - 11 mg/kg PO q 12 hrs
Amphetamine CNS stimulation during certain toxicoses 5 mg PO q 12 hrs
Amphotericin B Systemic mycoses 0.15 - 1 mg/kg in 5% dextrose IV q 48 hrs to a total cumulative dose of 10mg/kg
SQ diluted 1:10 in saline
Ampicillin Susceptible infections 20 - 60 mg/kg PO q 8 - 12 hrs
Amprolium Coccidiosis 60 - 100 mg/kg PO q 24 hrs x 5 d
With sulfadimethoxine 150 mg/kg PO q 24 hrs x 5d
Ascorbic acid Antioxidant 25 - 125 mg/kg/day PO q 24hrs
Acetaminophen toxicosis 30 mg/kg PO, SQ 6 - 7 treatments
Asparaginase Lymphosarcoma 10,000 U/m2 IV weekly as part of a protocol
Aspirin Antipyretic 6 - 10 mg/kg PO q 48 - 72hrs
Atenolol ß1-blocker for Hypertrophic cardiomyopathy + Hypertension 6.25 mg/cat PO q 24hrs
Atipamezole Medetomidine reversal equivolume IM as needed
Atovaquone Toxoplasma spp, Babesia spp, Pneumocystis spp 10 - 15 mg/kg with fatty meal PO q 8 hrs x 21 days
Atracurium Paralytic anaesthetic agent 0.1 - 0.25 mg/kg IV repeated q 30mins
Atropine Pre-anaesthetic medicant, Sinus bradycardia 0.02 - 0.04 mg/kg IM, IV, SQ as required
Organophosphate toxicity 0.2 - 2.0 mg/kg IM, SQ q 2hrs
Aurothioglucose Pemphigus, periodontitis and pododermatitis 1 - 2 mg IM weekly
Azathioprine Enteritis 0.2 -0.3 mg/kg PO q 24 - 48hrs
Immune-mediated haemolytic anaemia 1 mg/kg PO q 24 - 48hrs
Immunosuppression 1.1 mg/kg PO q 48hrs
Azithromycin Susceptible infections 5 mg/kg PO q 24 - 48 hrs
Susceptible infections 80 mg stat PO weekly x 3
Azodyl Probiotic 1 capsule PO q 12 - 24 hrs
Aztreonam Susceptible infections 12 - 25 mg/kg IV, IM q 8 - 12 hrs
Baytril Susceptible infections 5.0 - 20.0 mg/kg PO, SQ, IM, IV (with caution - may cause blindness) q 24hrsfor 7 - 10 days
Beclomethasone Anti-inflammatory 200 mg Inhalant as required
Benazepril Afterload reduction (chronic renal disease, congestive heart failure) 0.25 - 0.5 mg/kg PO q 24hrs
Benzimidazole Trypanosomiasis 5 mg/kg PO q 24hrs for 4 months
Benzocaine Local anaesthetic 1 - 5 ml SQ as required
Benzoyl peroxide Seborrhoea, antibacterial leave on skin for 10mins q 3 - 4 days for 2 weeks
Betamethasone Anti-inflammatory 0.1 - 0.2 mg/kg PO q 12 - 24hrs
Bethanechol Bladder atony, dysautonomia, cystitis 1.25 - 5.0 mg PO q 8- 12 hrs
Bisacodyl Constipation 2 - 5 mg/dog PO q 24hrs as needed
Bleomycin Chemotherapy 10 µg/m2 IV, SQ q 24hrs for 4 days, then weekly; max dose 200mg/m2
Bran Stool softener 1 - 2 teaspoons/400g food PO as needed
Brewer's yeast B vitamin source 0.2 mg PO q 24 hrs
Bromhexine hydrochloride Mucolytic for asthma 2 mg/kg PO q 12 hrs for 7 - 10 days
Bromide Anticonvulsant 30 - 60 mg/kg PO q 12 hrs
Bromocriptine Cushing's syndrome, False pregnancy, lactation cessation 10 - 30 µg/kg PO q 24 hrs for 10 - 16 days
Budesonide Asthma, ulcerative colitis 1 mg/dog PO daily
Bunamidine Cestodes - Taenia spp, Spirometra spp, Diphyllobothrium spp 20 - 50 mg/kg PO after 3 hr fast
Bupivicaine hydrochloride Local Anaesthetic 0.22 - 3.0 ml/cat Epidural stat
Buprenorphine Opioid analgesia 0.005 - 0.01 mg/kg IV, IM q 4 - 8 hrs
Buspirone Behavioural therapy 0.5 - 1.0 mg/kg PO q12-24hrs
Busulfan Chronic myelocytic leukaemia 3 - 4mg/m2 or 0.1 mg/kg PO q 24 hrs
Butorphanol Preanesthetic 0.05 - 0.4mg/kg with ACP IV, IM, SQ
Antiemetic 0.2 - 0.6 mg/kg SQ, IM, IV
Analgesia 0.1 - 0.8 mg/kg PO q 6 - 12 hrs
Cabergoline Induction of estrus/abortion/pyometra 5 μg/kg/day PO, SQ q 24 hrs
Calcitriol Hypoparathyroidism, hyperparathyroidism 1.5 - 3.0 ng/kg PO q 24 hrs
Calcium carbonate Nutritional supplement 1/2 tsp PO daily
Phosphate binder 60 - 100 mg/kg PO daily
Calcium chloride 10% Ventricular asystole 1 ml/9kg or 0.1 - 0.3ml/kg IV (slowly) stat
Hypocalcaemia 1 ml/9kg IV stat
Calcium citrate Calcium replacement, cystitis 10 - 30 mg/kg PO q 8 hrs
Calcium EDTA Lead poisoning 100 mg/kg/day SQ daily for 5 days
Calcium gluconate Ventricular asystole 0.5 - 1.5 ml/kg IV (slowly) as required
Hypocalcemia, hyperkalemia 0.5 - 1.5 ml/kg IV (slowly) as required
Capstar Fleas 1 tab PO daily as needed
Captopril Vasodilator 2 - 3 mg/dog PO q 8 - 12 hrs
3 - 6.25 mg/dog PO q 12 hrs
Carbenicillin cystitis 10 - 55 mg/kg PO q 8hrs
Carboplatin Chemotherapy 200 mg/m2 IV q 4 weeks
Carmustine Chemotherapy 50 mg/m2 IV q 6 weeks
Carprofen Analgesia 1 - 4 mg/kg SQ stat
0.5-1.0 mg/kg PO q 24hrs
Cartrofen Analgesia 1 - 4 mg/kg SQ stat
Cefadroxil Susceptible infections 10 mg/kg PO q 24 hrs for 1 - 4 weeks
Cefovecin Susceptible infections 8 mg/kg (0.5 cc) SQ q 2 weeks x 3
Cephalexin Susceptible infections 10 - 35 mg/kg PO q 8 - 12 hrs

Cerenia

Anti-emetic 1.0 mg/kg SQ/PO q 24 hrs for 4 days, then rest 2 days
Charcoal, activated Adsorbent for poisonings 1 - 8 g/kg PO as needed
Chlorambucil Chemotherapy, ulcerative colitis 0.1 - 0.5 mg/kg PO q 48 - 72 hrs
pemphigus 0.1 - 0.2 mg/kg PO q 48 hrs with prednisolone
Chloramphenicol Susceptible infections 10 mg/kg PO q 12hrs
Chlorhexidine 0.5% Burns dilute 1:40 with saline topically q 24hrs
Chlorothiazide Diuretic 10 - 40 mg/kg PO q 12 hrs
Partial ADH deficiency 20 - 40 mg/kg PO q 12 hrs
Chlorpheniramine Antihistamine 1 - 2 mg/dog PO q 8 - 12 hrs
Chlorpromazine vomiting, pancreatitis 0.2 - 0.5 mg/kg IM or SQ q 6-8hrs
Cholecalciferol (Vit D) hyperparathyroidism, hypocalcaemia 500 - 2000 U/kg PO q 24 hrs
Chondroitin Arthritis 50 - 100 mg/dog PO q 24 hrs
Cimetidine Oesophagitis, antiemetic, gastritis 5 - 15 mg/kg PO, IV, IM q 8 - 12 hrs
Ciprofloxacin Susceptible infections 11 - 15 mg/kg PO q 24 hrs
Cisapride (Prepulsid) constipation, megacolon 0.5 - 5.0mg/cat PO q 12 hrs
Cisplatin Chemotherapy 100 mg/m2 IV q 4 weeks x 2
Clarithromycin Mycobacterium spp 50 mg/dog PO q 12 hrs
Clavulox Susceptible infections 10 - 20 mg/kg PO q 12 hrs
Clindamycin Anaerobic infections 5 - 11 mg/kg PO q 12 hrs
Stomatitis, Pancreatitis 22 mg/kg PO q 24 hrs
Exocrine pancreatic insufficiency 5 - 10 mg/kg PO q 6 - 8 hrs
Enteroepithelial cycle 12.5 - 50 mg/kg PO q 12 hrs
Clofazimine Mycobacterium spp 4 - 8 mg/kg PO q 24 hrs for 6 weeks
50 mg/cat PO q 48 hrs
Clomipramine obsessive compulsive disorders, aggression 0.5 - 2.0 mg/kg PO q 12 - 24 hrs
Clonazepam Seizures, obsessive compulsive disorders, separation anxiety 0.5 mg/kg PO q 8 - 12 hrs
Clopidogrel thromboembolism, hypertrophic cardiomyopathy 18.75 - 75 mg PO q 24 hrs
Clorazepate separation anxiety 1 - 2 mg/kg PO q 8 - 12 hrs
Clotrimazole Fungal infections apply to lesion topical q 12 hrs
Fungal infections 60 ml of 1 g/dL of polyethylene glycol intranasal over 1 hr under general anaesthesia
Cloxacillin Susceptible infections 20 - 40 mg/kg PO, IM, IV q 4 - 8 hrs
Coal tar shampoos Seborrhoea Keep in contact with skin for 10 mins Topically q 24 hrs
Cobalamin see Vit B12
Cod liver oil 1 teaspoon / 10 kg
Codeine Pain relief 0.5 - 4 mg/kg PO q 6 - 12 hrs
Antitussive, analgesia 0.1 - 0.3 mg/kg PO q 4 - 6 hrs
Colchicine Antifibrotic 0.01 - 0.3 mg/kg PO q 4 - 6 hrs
Colony stimulating factor cyclic neutropenia 2.5 - 5.0 mg/kg (3 × 107 IU/kg) SQ q 24 hrs
Convenia Susceptible infections 8 mg/kg (0.5 cc) SQ q 2 weeks x 3
Corticotrophin gel (ACTH) Response test pre-ACTH sample 0.5 - 2.2 IU/kg IM
Cortisone acetate hypoadrenocorticism 1 mg/kg PO, IM q 24 hrs
Cosyntropin pre-ACTH sample 0.125 mg/dog IV
Cyanocobalamin Vit B12 deficiency 50 - 1000 µg PO, IM, SQ q 24 hrs
Cyclizine Antiemetic 4 mg/kg IM q 8 hrs
Cyclophosphamide Chemotherapy 100 mg/m2 PO q 3 weeks with doxorubicin
Cyclosporin thrombocytopenia, pemphigus, sebaceous adenitis 4 - 6 mg/kg 4hr IV infusion q 24 hrs (avoid extravasation)
3 - 7 mg/kg PO q 12 hrs
Cyclosporin ophthalmic keratoconjunctivitis sicca 1 - 2% solution drop in eye q 12 hrs
Cyclothiazide diuretic 0.5 - 1.0 mg/kg PO q 24 hrs
Cytarabine Chemotherapy 30-50 mg/kg IV, IM, SQ once a week
100 mg/m2 IV. IM, SQ q 24 hrs for 4 days then
20 mg/m2 Intrathecal q 24 hrs for 1 - 5 days
Dacarbazine Lymphoreticular neoplasms 200 - 250 mg/m2 IV q 24 hrs for 5 days, every 21 days
Soft tissue sarcomas 1000 mg/m2 IV infusion over 6 - 8hrs, every 21 days
Dactinomycin Chemotherapy 0.015 mg/kg IV q 24 hrs for 3 - 5 days, wait 3 weeks then
0.1 - 1.5 mg/m2 IV weekly
Dalteparin DIC, Thrombosis 70 IU/kg SQ q 24 hrs
Dapsone Mycobacterium spp 1.1 mg/kg PO q 12 hrs for 4 - 6 weeks
Deferoxamine mesylate Iron chelator 10 mg/kg IV, IM, SQ q 2 hrs for 2 doses then q 8 hrs for 24 hrs
Reperfusion (ischaemia) injuries 50 mg/kg IV over 5 mins
Deprenyl hyperadrenocorticism 1 - 2 mg/kg PO q 24 hrs
Desmopressin acetate diabetes insipidus 0.3 µg/kg IM q 12 - 24 hrs
Desoxycorticosterone acetate hypoadrenocorticism 0.2-0.4 mg/kg conjunctivally q 24hrs, max 5mg
Desoxycorticosterone pivalate hypoadrenocorticism 25 mg IM stat
Dexamethasone central oedema, spinal cord trauma, DJD, other CNS trauma 2 mg/kg IV then,
1 mg/kg IV, SQ q 8 - 12 hrs, then
0.1 mg/kg IV, SQ, PO q 8-12hrs
hydrocephalus 0.25 mg/kg IV, IM, PO q 6 - 8 hrs
shock, anaphylaxis 4 - 6 mg/kg IV (slowly)
immune-mediated disease 0.25 - 1.25 mg/kg PO q 12 - 24 hrs
0.1 - 0.15 mg/kg SQ, PO q 12 hrs for 5 - 7 days, then taper dose
hypoadrenocorticism 0.1 - 0.5 mg/kg SQ, IV with mineralocorticoids
asthma 1 mg/kg IV then
0.25 - 1.0 mg/cat PO q 8 - 24hrs
Dexrazoxane iron chelation for doxorubicin-induced cardiotoxicity 25 mg/kg (ratio of 10-20:1 dexrazoxane : doxorubicin) IV 15 mins before doxorubicin
Dextran 40 Shock 10 - 20 ml/kg IV q 24 hrs
Dextran 70 Volume expander 10 - 20 ml/kg IV q 24 hrs to effect
Dextromethorphan coughing 0.5 - 2.0 mg/kg PO, SQ, IV q 6 - 8 hrs
Dextrose, 50% hypoglycemia, insulin overdose 2 ml/kg PO
0.25 - 1.0 ml/kg IV
Dextrose, 5% hypoglycemia, insulin overdose 40 - 50 ml/kg IV, SQ, IP as needed
Diazepam Pre-med, Behavior modification 0.5 - 2.2 mg/kg PO as needed
seizures 0.15 - 0.70 mg/kg PO, IV q 8 hrs
status epilepticus, toxins 0.5 - 1.0 mg/kg IV in increments of 5 - 20 mg
strychnine-induced seizures 2 - 5 mg/kg IV as needed
0.5 mg/kg IV
Dichlorphenamide Glaucoma 3 - 5 mg/kg PO q 8- 12 hrs
Dicloxacillin Susceptible infections 10 - 50 mg/kg PO q 6 - 8 hrs
Diethylcarbamazine heartworm disease 6.6 mg/kg PO q 24 hrs
Diethylstilboestrol incontinence 0.01-0.02 mg/kg PO q 24 hrs
Difloxacin Susceptible infections 5 - 10 mg/kg PO q 24 hrs
Digoxin Congestive heart failure 0.005 - 0.008 mg/kg PO q 12 hrs
Dihydrotachysterol milk fever, hypoparathyroidism 0.03 - 0.06 mg/kg PO q 24 hrs for 3, then
0.01-0.02 mg/kg PO q 24hrs
Diltiazem hypertension, hypertrophic cardiomyopathy, supraventricular tachycardia 0.5 - 2.5 mg/kg PO q 8 hrs
Dimenhydrinate Antihistamine 1.0 - 3.0 mg/kg PO, IM, IV as needed
Dimercaprol Arsenic toxicosis 2.5 -5.0 mg/kg IM q 4 hrs for 2 days, then q 8hrs for 3 days, then q 12hrs for 10 days
Dimethylsulfoxide Spinal cord trauma, amyloidosis 0.5 - 1 g/kg IV (10%) q 6 - 8 hrs over 45 min
Diminazine aceturate Babesia spp, Trypanosoma spp 2.0 - 3.5 mg/kg IM Once
3.5 mg/kg IM, SQ q 24 hrs for 2 days
Dinoprost see prostaglandin F2a
Diphenhydramine Antihistamine 2 - 4 mg/kg PO q 6 - 8 hrs
mast cell tumour, antiemetic 2 mg/kg IM, IV q 12 hrs as needed
Diphenoxylate ulcerative colitis 0.05 - 0.1 mg/kg PO q 12 hrs
Diphenylthiocarbazone Thallium toxicosis 50 - 70 mg/kg PO q 8 hrs
Diphemanil methylsulphate bronchodilator 1.8 mg/kg IM q 12 hrs
Dipyridamole thromboembolism 4 - 10 mg/kg PO q 24 hrs
Disodium EDTA Calcium keratopathy 0.37% solution topically lavage cornea for 15 - 20 mins
Dobutamine Positive ionotrope 0.5 - 2.0 µg/kg/min IV infusion (caution) 1 min
Dolasetron antiemetic 0.6 mg/kg PO, IV, SQ q 24 hrs
Dopamine hypotension, shock, inotropic agent 2 - 25 µg/kg IV infusion 1 min
Doxapram Respiratory stimulant in neonates 1 - 5 mg/kg IV (umbilical vein) as needed
1 - 2 drops PO as needed
Doxorubicin chemotherapy 10 - 30 mg/m2 IV q 21 days
Doxycycline Susceptible infections 5 - 10 mg/kg PO, IV q 12 - 24 hrs
Edrophonium myasthenia gravis diagnosis 2.5 mg/dog IV stat
Emodepside anthelmintic 1 x vial topically monthly
Enalapril hypertension, congestive heart failure, valvular endocardiosis 0.25 - 0.5 mg/kg PO q 12 - 24 hrs
Enilconazole 10% Aspergillus spp 5% solution (1:1 in water) topically q 12 hrs for 7 - 10 days
10-20 mg/kg (10% solution: 50:50 in water instil into nasal sinus q 12hrs for 10 - 14 days
Enrofloxacin Susceptible infections 5.0 - 20.0 mg/kg PO, SQ, IM, IV (with caution - may cause blindness) q 24 hrs for 7 - 10 days
Ephedrine bronchodilator, incontinence 2.0 - 5.0 mg/kg PO q 8 - 12 hrs
Epinephrine cardiac arrest 0.2 ml/kg IV, intratracheal q 5 - 15 min as needed
Epsiprantel Dipylidium spp, Taenia spp 2.5 - 2.75 mg/kg PO stat
Ergocalciferol Vitamin D 500 - 2000 IU/kg PO q 24 hrs
Erythromycin Susceptible infections 10 - 22 mg/kg PO, IV q 8 hrs
Erythropoietin anemia 50 - 100 IU/kg SQ 3 x weekly for 12 weeks then twice weekly (as need to maintain PCV at 35%)
400 IU/kg IV, SQ once a week
Esmolol Selective B1 blockade 0.05 mg/kg slow IV loading dose, then
50 - 200 µg/kg IV infusion per min
Estradiol cypionate mesalliance 125 - 250 µg IM between 40hrs and 5 days post-coitus
Ethosuximide seizures 40 mg/kg PO load, then
20 mg/kg PO
EDTA anticoagulant, chelation 1 mg/kg IV q 2hrs
Etidronate disodium hypercalcaemia 10 mg/kg PO q 2 hrs
Etomidate general anesthesia 0.5 - 3.0 mg/kg IV as needed
With opioids 0.5-1.0 mg/kg IV as needed
Etretinate dermatopathy 1 - 2 mg/kg PO q 24 hrs
Famotidine antacid 0.5 mg/kg IM, SQ, PO q 12 - 24 hrs
Febantel anthelmintic 10 mg/kg per 1mg/kg praziquantel PO q 24 hrs for 3 days
Fenbendazole anthelmintic 25 - 50 mg/kg PO q 12 hrs for 3-14 days
Fentanyl analgesia 0.01 mg/kg IV, SQ, IM
Fitergol cognitive dysfunction syndrome 1 - 5 mg/dog PO q 24hrs
Flavoxate Incontinence (Detrusor hyperspasticity) 100 - 200 mg/dog PO q 6 - 8 hrs
Florfenicol Susceptible infections 22 - 50 mg/kg PO, IM, SC q 12 hrs
Fluconazole fungal infections 2.5 - 10.0 mg/kg PO with food q 12 - 24 hrs
Flucytosine Cryptococcus spp 30 - 50 mg/kg PO q 6 - 8 hrs
Fludrocortisone hypoadrenocorticism 0.1 - 0.2 mg/dog PO q 24 hrs
Flumazenil hepatic encephalopathy 0.2 mg/dog IV as needed
Flumethasone anti-inflammatory 0.15 - 0.3 mg/kg IV, IM, SQ q 24 hrs
Flunixin meglamine analgesic, anti-pyretic 0.5 - 2.2 mg/kg IV, IM, SQ oid for 3 days, then repeat after 4 days
Fluoxetine Behavioural problems 0.1 - 2.0 mg/kg PO q 24 hrs
Flurazepam seizures 0.2 - 0.4 mg/kg PO q 4 - 7 days
Flurbiprofen Conjunctivitis 0.2 - 0.4 mg/kg Topically q 8 - 12 hrs
Folic acid Dietary supplement 0.5 - 1.0 mg/kg PO q 24 hrs
Follicle stimulating hormone (FSH) Induction of oestrus 500 IU HCG IV, IM, SQ q 24 hrs for 5 days
Fomepizole Ethylene glycol toxicity 20 mg/kg IV stat
Furosemide diuretic 2 - 4 mg/kg IV, IM, PO q 8 - 12 hrs as needed
Gabapentin Epilepsy 10 mg/kg PO q 8 - 12 hrs
Gamma globulin Immune-mediated disease 1 g/cat IV q 6 - 12 hrs
Gentamicin Susceptible infections 6 - 8 mg/kg IM, SQ, IV q 24 hrs
Glimipiride Non-insulin-dependant diabetes mellitus 0.25 - 0.5 mg/kg PO q 24 hrs
Glipizide Non-insulin-dependant diabetes mellitus 0.25 - 0.5 mg/kg PO q 8 - 12 hrs
Glycopyrrolate Bundle branch block 0.005 - 0.010 mg/kg IV, IM as needed
Gold sodium thiomalate Immune-mediated disease 0.25 - 1.0 mg/kg IM weekly x 3; 2nd + 3rd week at 2 - 10 mg/cat
Gonadotropin releasing hormone (GnRH) Ovarian cystadenoma, detection of ovarian remnant syndrome 25 µg/dog IM single treatment
Granisetron Chemotherapy-associated vomiting 0.1 - 0.5 mg/kg IV, PO q 12 - 24 hrs
Granulocyte colony stimulating factor Neutropenia 3 - 10 µg/kg SQ q 12 - 24 hrs
Griseofulvin Antifungal 10 - 30 mg/kg PO q 24 hrs for 4 weeks
Guaifenesin Tranquiliser 44 - 88 mg/kg IV stat
Halofuginone Coccidiostat, Immunosuppressant 100 µg/kg PO q 24 hrs
Halothane General anesthesia Induction: 3% Inhalant stat
Maintenance: 0.5-1.5% Inhalant as needed
Haemoglobin (polymerised bovine) Blood replacement 10-30 ml/kg IV stat
Heparin Thromboembolism, thrombophlebitis Initial dose: 100-200 IU/kg IV then
Maintenance dose: 50-100 IU/kg SQ q 6 - 8hrs
Thromboembolism Induction 1000 IU/kg IV then
Maintenance: 50 IU/kg SQ q 8hrs
Pancreatitis 50-1000 IU/kg SQ q 8 - 12hrs
DIC 75-100 IU/kg IV, SQ q 6hrs
Lipoprotein lipase provocation test 100 IU/kg IV test lipids before and 15 mins after heparin
Heparin, LMW see Dalteparin
Hetacillin Susceptible infections 10 - 20 mg/kg PO q 8 - 12 hrs not associated with feeding
Hetastarch (Hydroxyethyl starch) Plasma volume expander 10 - 20 ml/kg IV as needed
Human gammaglobulin Immune-mediated disease 0.5 - 1.5 g/kg IV q 12 hrs (infusion)
Hydrocodone Antitussive 0.22 mg/kg PO q 12 hrs
Hyaluronate sodium Synovitis 0.5 - 1.0 mg/kg intra-articular q 7 days
Hydralazine Vasodilator: congestive heart failure 0.5 mg/kg, titrate up to 0.5 - 0.8 mg/kg PO q 12 hrs
Hydrochlorothiazide Hypertension 0.5 - 2.0 mg/kg PO q 12 - 24 hrs
Nephrogenic diabetes insipidus 0.5 - 5.0 mg/kg PO q 12 hrs
Hypoglycaemia 2 - 4 mg/kg PO q 12 hrs
Calcium oxalate uroliths 2 mg/kg PO q 12 hrs
Hydrocortisone Replacement therapy 0.5 - 1.0 mg/kg PO q 24 hrs
Anti-inflammatory 2.5 - 5.0 mg/kg PO q 12 hrs
Hydrocortisone aurate Hypoadrenocorticism 0.1 - 0.2 mg/kg IM q 8 - 12 hrs
Immune-mediated haemolytic anaemia 2 - 4 mg/kg IM q 12 - 24 hrs
Hydrocortisone sodium succinate Shock 8 - 150 mg/kg IV stat
Hydrogen peroxide (3%) Emetic 5-10 ml/cat PO stat
Hydromorphone Analgesia 0.05 - 0.1 mg/kg IM, SQ every 24 hrs
Hydroxyurea Primary polycythemia 25 - 30 mg/kg PO q 3 days
Chronic granulocytic leukaemia 0.5 g/m2 PO q 12hrs for 4-6 weeks, then halve dosage
Hydroxyzine Antihistamine 5-10 mg/cat PO q 12hrs
Hypertonic saline Shock 2-6 ml/kg rapid IV infusion stat
Idarubicin HCl Antiviral 2.0 mg/kg PO q 24hrs for 2 days, then repeat q21 days
Idoxuridine Ocular herpes viral infection 0.1% solution: 1 drop topically q 4 - 6 hrs
0.5% ointment topically q 1 hr
Imatinib mesylate Chemotherapy 10 mg/kg orally once daily
Imidacloprid Fleas 100 mg/ml topically 0.1 cc/kg monthly
Imidocarb Ehrlichia spp 5 mg/kg IM every 14 days x 2
Imidapril Congestive heart failure and Chronic renal disease 0.5 mg/kg PO q 24hrs
Imipenem-cilastin Susceptible infections 2 - 10 mg/kg IM or slow IV q 6 - 8 hrs
Imipramine Behavioural modification, urinary incontinence 2.5 - 5.0 mg/cat PO q 12 hrs
Insulin, glargine Diabetes mellitus 0.25-5.0 U/kg SQ q 12hrs, adjust as needed
Insulin, lente Diabetes mellitus 0.5 U/kg SQ q 12 - 24hrs
Insulin, NHP Diabetes mellitus 1 - 3 U/dog SQ q 12 - 24hrs
Insulin, PZI Diabetes mellitus 1 - 3 U/dog SQ q 12 - 24 hrs
Insulin, regular Diabetes mellitus 1 - 2 U/dog SQ q 6 - 8 hrs
Insulin, ultralente Diabetes mellitus 1-3 U/dog SQ q 12 - 24hrs
Interferon a2, human recombinant Immunostimulant 15 - 30 U/dog IM, SQ, PO q 24 hrs on alternate weeks
Iodine Hyperthyroidism 50 - 100 mg/dog PO q 24 hrs
Iodide sodium, potassium 20% solution Hyperthyroidism 20 mg/kg PO q 12 - 24 hrs
Iopamidol Myelography 0.25 ml/kg intrathecal stat
Ipecac syrup Emetic 2 - 6 ml/dog PO stat
Ipodate Hyperthyroidism (short term) 15 mg/kg PO q 12hrs
Iron dextran anemia 50 mg IM at 18 days of age
Isoflurane Gaseous anaesthesia

Induction: 5%

Maintenance: 1.5-2.5%

Inhalation stat
Isoniazid Mycobacterium spp 10 - 20 mg/kg PO q 24 hrs
Isopropamide Bundle branch block 0.2 - 0.4 mg/kg PO q 8 - 12 hrs
Antidiarrhoeal, GIT hypermotility 0.2 - 1.0 mg/kg PO q 12 hrs
Isoproterenol Bundle branch block 0.04 - 0.08 µg/kg IV infusion as needed
Isosorbide dinitrate Vasodilator, osmotic diuretic, megaoesophagus 2.5 - 5.0mg PO q 12 hrs
Itraconazole fungal infections 5 - 10 mg/kg PO q 12 - 24 hrs
Ivermectin Heartworm disease prophylaxis 24 µg/kg PO once monthly
Kanamycin Susceptible infections 10 - 15 mg/kg IV, IM, SQ q 12 hrs
GI tract bacterial overgrowth 10 - 12 mg/kg PO q 8 - 12 hrs
Kaolin / pectin GI tract protectant 1 - 2 ml/kg PO q 2 - 6 hrs
Ketamine general anesthesia 7 - 11 mg/kg IV, IM stat
Ketoconazole fungal infections 5.0 - 10.0 mg/kg PO q 12 - 24 hrs
Ketoprofen analgesic 0.2 - 1.0 mg/kg PO, IM, SQ q 24 hrs for less than 5 days
L-asparaginase chemotherapy 10,000 U/m2 IV weekly as part of a protocol
Lactated Ringer's solution Rehydration 40 - 50 ml/kg IV q 24 hrs
Lactilol Stool softener, hepatic encephalopathy 250 ml PO q 12 hrs
Lactoferrin periodontitis 40 mg/kg Topical q 24 hrs
Lactulose megacolon, hepatic encephalopathy 2.5-5.0 ml PO q 8 - 12 hrs
Lamasil fungal infections 20 - 30 mg/kg PO q 24 hrs for 4 - 10 weeks
Leucovorin Methotrexate toxicity 3 mg/m2 IM within 3 hrs of poisoning
Levallorphan Opioid toxicity/overdose 0.02 - 0.20 mg/kg IV as needed
Levamisole heartworm disease 10 mg/kg PO q 24 hrs for 7 days
Levetiracetam seizures, cognitive disorder 15 - 20 mg/kg PO q 8 - 12 hrs
Levodopa hepatic encephalopathy 6.8 mg/kg initially, then 1.4mg/kg PO q 6 hrs
Thyroxine Hypothyroidism 10-30 µg/kg PO q 12hrs
Lidocaine Ventricular arrhythmias, epidural 0.25 - 1.0 mg/kg IV, intrathecal stat
Lime sulphur Sarcoptes spp 1:40 dilution Topically weekly for 6 weeks
Lime water Alkaline gastric lavage 5 ml/kg PO stat
Lincomycin Susceptible infections 11 - 33 mg/kg PO, IV, IM q 12 - 24 hrs
Lisinopril congestive heart failure, hypertension 0.25 - 5.0 mg/kg PO q 24 hrs
Lobaplatin chemotherapy 35 mg/m2 IV q 3 hrs
Lomustine chemotherapy 100-150 mg/m2 PO q 6 weeks (subsequent dose based on WBC)
Loperimide Antidiarrhoeal 0.1 - 0.3 mg/kg PO q 12 - 24 hrs
Luteinizing hormone Stimulate ovulation 50 IU IM after mating
Magnesium sulphate (25%) Hypomagnesemia 5 - 15 mmol IM, IV over 1 - 2 hrs
Mannitol 5-20% oliguric renal failure 0.25 - 1.0 g/kg IV over 15 - 60 min q 4 - 6 hrs to maintain urine flow
Glaucoma 1 - 3 mg/kg IV over 15 - 20 min
CNS oedema 1.5 mg/kg IV stat
Marbofloxacin Susceptible infections 2.75 - 5.5 mg/kg PO q 24 hrs
Maropitant Anti-emetic 1.0 mg/kg SQ/PO q 24 hrs for 4 days, then rest 2 days
Mebendazole Parasites 22 mg/kg PO q 24 hrs for 3 days
Meclizine antiemetic 12.5 mg PO q 24 hrs, 1 hr before driving
Medetomidine analgesia, sedative 50-150 µg/kg IV, IM stat
Medroxyprogesterone acetate aggression 1 - 2 mg/kg IM once weekly, stop 7-10 days before parturition
Megestrol acetate estrus suppression 0.5 - 1.0 mg/kg PO q 24 hrs for 10 days, then q 48hrs for 5 treatments, then as needed
Meglumine antimonate Leishmaniasis 5 - 30 ml/dog IV, IM, IP q 48 - 72 hrs
Melatonin Anterior uveitis 0.01 - 1.0 mg PO q 24hrs
Meloxicam analgesia 0.01 - 0.03 mg/kg PO q 24 hrs as needed
Melphalan chemotherapy 0.05 mg/kg PO q 24 hrs for 2 weeks, then q 48hrs
Mepivacaine Local analgesia 1 - 5 ml of 2% solution SQ as needed
Mesna Haemorrhagic cystitis associated with cyclophosphamide 40% of cyclophosphamide dose PO, IV, IM, SQ q 3 hrs x 6 at time of cyclophosphamide treatment, follow with repeat dose (24 hr infusion)
Metamucil Laxative 2-4 g in moistened food q 12 - 24 hrs
Metaproterenol Bronchodilation 0.325 - 0.65 mg/kg PO q 4 - 6 hrs
Metaraminol Vascular support during shock 0.01 - 0.1 mg/kg IV slowly stat
Metformin diabetes mellitus) 2 mg/kg PO q 12 hrs
Methazolamide glaucoma 1 - 2 mg/kg PO q 12 hrs
Methicillin Susceptible infections 20 mg/kg IM, IV q 6 hrs
Methocarbamol Muscle relaxation 20 - 66 mg/kg PO q 8 - 12 hrs
Methohexital Anaesthesia induction 2.5% solution: 11 mg/kg IV stat
Methotrexate sodium Chemotherapy 2.5 mg/m2 PO q 24hrs or 2 - 3 x weekly, in a protocol on day 14 with 5 mg prednisolone PO q 12hrs
Carcinomas, sarcomas 10-15 mg/m2 PO q 1 - 3 weeks
Methoxamine (a1-agonist) Vasopressor: cardiac arrest, shock 200-250 µg/kg or 40-80 µg/kg IM stat
Methoxyflurane Inhalation anaesthesia Induction: 3%, Maintenance: 0.5-1.5% Inhalation stat
Methscopolamine bromide Anti-emetic 0.3-1.0 mg/kg PO q 8hrs (use cautiously)
Methylcellulose Laxative 1.0-1.5 g/cat PO as needed
Methylene blue 0.1% Indicator dye 3 mg / 250 ml 0.9% NaCl IV over 30-40 min
Antidote 1-1.5 mg/kg IV stat
Methylprednisolone Antiinflammatory 0.5-1.0 mg/kg PO q 12hrs
Methylprednisolone acetate Asthma 1-2 mg/kg IM q 7 days
Others 5.5 mg/kg SQ, IM 1 - 24 weeks
Methyltestosterone Anabolic steroid 1 - 2 mg/kg PO q 24 hrs
Testosterone-responsive dermatoses 1-2.5 mg/cat PO q 48hrs
Metoclopramide Gastric motility disorders, antiemetic 0.2 -0.5 mg/kg PO, IM, SQ q 8 hrs
1.0 - 2.0 mg/kg IV q 24 hrs
Gastric reflux 0.2-0.4 mg/kg PO q 8hrs, 30 mins before meals
Metoprolol Atrial fibrillation, hypertrophic cardiomyopathy 0.05 - 3.0 mg/kg PO q 8 hrs
Metronidazole Colitis, Coccidiosis, anaerobic infections 10 - 25 mg/kg PO q 24 hrs for 7 - 14 days
Gingivitis 50 mg/kg PO q 24 hrs
Metyrapone Cushing's syndrome 65 mg/kg PO q 12 hrs
Mirtazepine Antiemetic 0.75 mg/kg PO q 3 days
Misoprostol Mucosal protectant 3 - 5 µg/kg PO q 12 hrs as required
Miconazole cream Fungal infections 1 - 3 cm topically q 24 hrs for 2 - 4 weeks
Midazolam Preanaesthetic, sedation, 0.06 - 0.22 mg/kg IM, IV stat
Control of seizures 0.2-0.5 mg/kg IV stat
Milbemax Heartworm and intestinal worm prophylaxis 0.5 - 2.0 mg/kg PO monthly
Silymarin Free radical scavenger 50 - 250 mg/kg PO q 12 hrs
Mineral oil Laxative 5-10 ml/cat PO, per rectum q 12hrs
Mithramycin Hypercalcaemia, testicular cancer, malignancies 0.25 - 0.50 µg/kg IV q 24 hrs x 2
Mitotane (o,p-DDD) Pituitary-dependant hyperadrenocorticism 25 mg/kg PO q 7 days (maintenance)
Mitoxantrone Anticancer chemotherapy 6.0 - 6.5 mg/m2 IV q 3 - 4 weeks x 4 - 6
Morphine Antitussive, analgesia 0.05 - 0.1 mg/kg SQ, IM q 4 - 6 hrs
Moxifloxacin Mycobacterium spp, Bartonella spp]] 5.0 mg/kg PO q 24 hours
Naloxone stereotypic behaviour 20 mg SQ
Shock 2 mg/kg IV q 1 hr
Opioid antagonist 0.01 - 0.04 mg/kg IV to effect, repeat as needed
Nandrolone Anaemia 2.0 - 10 mg/kg IM weekly
N-acetylcysteine see Acetylcysteine
Neomycin Susceptible infections 7 mg/kg IM, IV, SC q 24 hrs (nephrotoxic)
Hepatic encephalopathy 10 - 20 mg/kg per rectum q 6 hrs
Neostigmine Diagnostic aid for myasthenia gravis 20 µg/kg with 0.04 mg/kg of atropine IV stat
2 mg/kg/day PO q 24hrs, divided doses
Niacin Hypertriglyceridemia 50 - 100 mg/day PO q 24 hrs
Nitenpyram Fleas 1 tab PO daily as needed
Nitroglycerin 2% ointment Vasodilator for pre-load reduction 1/8 - 1/4 inch (0.3-0.6cm) cutaneously q 6 - 8 hrs
Nitroprusside Acute Congestive heart failure 0.5-10 µg/kg IV q 1 min
Norepinephrine Positive ionotrope 0.05 - 0.3 µg/kg IV q 1 min
Novobiocin Susceptible infections 10 mg/kg PO q 8 hrs
Nystatin Susceptible infections 100,000 IU PO q 8 hrs
Octreotide Chylothorax, Acromegaly 0.1 mg SQ q 8 hrs
Ofloxacin Susceptible infections 2.5-10.0 mg/kg PO q 12hrs
Omeprazole Gastritis, gastric ulceration 1 mg/kg PO q 24 hrs
Ondansetron Antiemetic 0.5 - 1.0 mg/kg PO q 24 hrs
Orbifloxacin Susceptible infections 2.5 - 7.5 mg/kg PO q 24 hrs
Ovarid (see Megestrol acetate)
Oxymorphone Preanaesthetic 0.1 - 0.2 mg/kg IM, IV with ACP or atropine
Oxytocin Dystocia 0.5 - 1.0 IU/kg IV, IM, SQ q 2 hrs for max of 3 doses
Paclitaxel Chemotherapy 5 mg/kg IV pre-treat for anaphylaxis
Pancuronium bromide Paralytic agent for controlled anaesthesia 0.044 - 0.11 mg/kg IV stat
Parvaquone Toxoplasmosis 10 - 30 mg/kg IM q 24 hrs
D-penicillamine chronic hepatitis 10 - 15 mg/kg PO q 12 hrs
Penicillin G Susceptible infections 20-30 mg/kg PO q 6 - 8hrs
Pentazocine Analgesia 2.2 - 3.3 mg/kg IV, IM, SQ q 4 hrs
Pentobarbital general anesthesia 25 - 30 mg/kg IV to effect
Status epilepticus 5 - 15 mg/kg IV to effect
Sedation 2 - 4 mg/kg PO q 6 hrs
Pentosan polysulfate Disease modifying agent, arthritis 3 mg/kg IM, SQ q 7 days
Pentoxifylline Dermatomyositis 20 mg/kg PO q 8 - 12 hrs
Autoimmune skin diseases 10 - 15 mg/kg PO q 24hrs
Phenamidine isethionate Babesia spp 7.5 mg/kg IM, SQ q 24hrs x 2
Phenobarbital Status epilepticus 2.5 - 5 mg/kg PO, IM, IV q 12 hrs
Phenoxybenzamine Hypertension, pheochromocytoma 0.5 mg/kg PO q 12 hrs
Detrusor areflexia 0.5 - 2.0 mg/cat PO q 8 - 12 hrs
Relaxation of urinary sphincter 0.5 mg/kg IV stat
Endotoxemia 2.5-10.0 mg/cat PO q 24hrs
Phentolamine hypertension from pheochromocytoma 0.02 - 0.1 mg/kg IV stat
Phenylephrine Vasopressor, decongestant, mydriatic 0.15 mg/kg IV as needed
Phenylpropanolamine incontinence 1.5 - 2.0 mg/kg PO q 8 hrs
Phenytoin Seizures, ventricular arrhythmias 2 - 3 mg/kg PO q 24 hrs
Phosphate (K or Na) Hypophosphatemia 4.5 mg/dl serum phosphate IV over 6 hrs
Physostigmine (Syrup) Myasthenia gravis, Glaucoma, magic-mushroom intoxication 0.25-5.0 mg/cat IM q 12hrs
Phytomenadione See Vitamin K1
Pilocarpine 1% ophthalmic glaucoma 1 drop topically q 6 hrs
Pimaricin Ocular fungal infections 1 drop topically q 3 - 8 hrs
Piroxicam Analgesia, neoplasia 0.3 mg/kg PO q 24 - 72 hrs
Plicamycin Hypercalcemia, testicular cancer, malignancies 0.25 - 0.50 µg/kg IV q 24 hrs x 2
Polyethylene glycol Lubricant, intestinal cathartic 25 ml/kg PO then repeat in 2-4 hrs before GI exam
Polyethylene glycol electrolyte solution Electrolyte replacement 25 ml/kg PO q 2 - 4 hrs
Polymixin B Sepsis 1 - 2 mg/kg IV stat
Posaconazole Aspergillosis 2.5 - 3.75 mg/kg PO q 12 hrs
Potassium chloride Potassium supplementation 0.10-0.25 ml/kg PO q 8hrs
Hypokalemia 0.5 mEq/kg IV not to exceed 0.5 mEq/kg/hr
1 - 3 mEq PO. IV q 24 hrs
10-40 mEq/500 ml of fluid, depending on serum potassium IV, SQ stat
Potassium citrate Urolithiasis 50-75 mg/kg PO q 12hrs
Potassium gluconate Hypokalemia 5-8 mEq/dog PO q 12 - 24 hrs
Potassium iodide fungal infections 6 - 20 mg/kg PO q 24 hrs for 10-14 days
Potassium permanganate (1:2000) Strychnine toxicosis 5 ml/kg in gastric lavage PO stat
Potassium phosphate see Phosphate
Povidone-iodine Burns Apply light coating Topically q 12 - 24 hrs
Pradofloxacin Broad-spectrum antimicrobial 5 - 10 mg/kg PO, SQ q 24 hrs for 7 days
Pralidoxime chloride Organophosphate toxicosis 20 mg/kg IV, IM, SQ q 12 hrs
Praziquantel Dipylidium spp 5 mg/kg PO stat
Paragonimus spp 25 - 30 mg/kg PO q 24 hrs for 5-10 days
Prazosin After load reductions 0.5 - 2.0 mg/dog PO q 8 - 12hrs
Cystitis 0.07 mg/kg PO q 8 - 12 hrs
Prednisolone anti-inflammatory 1 - 2 mg/kg PO q 24 hrs (each evening)
Hypoadrenocorticism 1 mg/kg PO q 12 hrs
Prednisolone acetate Hypoadrenocorticism 0.1-0.2 mg/kg IM q 12hrs
Prednisolone sodium phosphate Shock 15 mg/kg IV q 4 - 6hrs
Prednisolone sodium succinate Allergic bronchitis, asthma 15-30 mg/kg IV, IM to effective dose
Shock 15-30 mg/kg IV q 4 - 6hrs
CNS trauma 15-30 mg/kg IV then taper to effective dose
Pregabalin Epilepsy 5 -10 mg/kg PO q 12 hrs
Prilium Congestive heart failure and Chronic renal disease 150 mg syrup PO 0.5ml q 24hrs
Procainamide Ventricular arrhythmias 62.5 mg/dog PO q 6hrs
Prochlorperazine Antiemetic 0.1 mg/kg IM q 6 hrs
Promazine hydrochloride Pre-anaesthetic 2.2 - 6.6 mg/kg IV stat
Antiemetic 1-2 mg/kg IM, IV q 4 - 6hrs
Promethazine HCl Antihistamine, antiemetic 0.2 - 0.4 mg/kg IV, IM, PO q 6 - 8 hrs
Propantheline bromide Acute colitis, ulcerative colitis, antiemetic 0.22 - 0.25 mg/kg PO q 8 hrs up to 3 days
Detrusor hyperspasticity, urge incontinence 0.2 mg/kg PO q 6 - 8hrs
Propriomazine Sedation 1.1-4.4 mg/kg IV, IM q 12 - 24hrs
Propofol General anaesthesia, status epilepticus Induction: 6 - 8 mg/kg IV stat
Induction: 2.5-4.0 mg/kg IV with premedication
Maintenance: 0.51 mg/kg IV q min
Propranolol Ventricular hypertrophy, aortic stenosis, HCM 0.4 - 1.2 mg/kg PO q 8 - 12 hrs
Ventricular arrhythmias 0.02 - 0.06 mg/kg IV over 2-3 min; q 8hrs
0.25-0.5 mg IV followed by
2.5 - 5.0 mg PO q 8hrs
hypertrophic cardiomyopathy, valvular insufficiency 2.5 mg/cat PO q 8 - 12hrs
Hypertension 2.5 - 5.0 mg/cat PO q 8 - 12 hrs
Tachyarrhythmias from endocrinopathies 2.5-5.0 mg PO q 8 - 12hrs
Propylthiouracil (PTU) Hyperthyroidism 10 mg/kg PO q 8 hrs
10 mg/kg PO q 8 - 12 hrs
Prostaglandin F2 alpha Pyometra, Cystic endometrial hyperplasia 0.10 - 0.25 mg/kg SQ q 24 hrs for 3 - 5 days
Abortion 0.5-1.0 mg/kg; 40 days post-conception SQ 2 injections 24 hrs apart
Protamine sulphate Heparin antagonist 1.0-1.5 mg for every 100 IU heparin IV stat
Pseudoephedrine Nasal decongestant 15 - 30 mg/dog PO q 8 - 12hrs
Urinary incontinence 0.2-0.4 mg/kg PO q 8 - 12hrs
Psyllium Bulk laxative 1 - 3 tsp PO q 8 - 12 hrs
Pyrantel pamoate Roundworm, hookworm 10 mg/kg PO repeat in 2 weeks
Pyridostigmine bromide Myasthenia gravis(acquired) 1-5 mg PO stat
0.25 mg/kg PO q 24hrs
Antidote (curariform) 0.15-0.30 mg/kg IM, IV
Toxoplasma 0.5-2.0 mg/kg PO q 12hrs for 14 - 28days
Enteroepithelial cycle 2 mg/kg PO q 24hrs for 14 - 28 days
Quinacrine Giardia spp, Coccidiosis 11 mg/kg PO q 24 hrs for 5 days
Ranitidine gastritis, GI tract ulceration 0.5 mg/kg IV, PO, SQ q 12 hrs
Retinol Dermatological lesions 625 - 800 IU/kg PO q 24 hrs
Rifampicin Susceptible infections 10 - 20 mg/kg PO q 24hrs
Ringer's solution Maintenance solution 40 - 50 ml/kg IV, SC, IP q 24hrs
Ronidazole (Ronivet) Tritrichomoniasis 30 mg/kg PO q 24 hrs for 14 days
(warning: low therapeutic margin) 20 mg/kg PO q 12 hrs for 14 days
Roxithromycin Susceptible infections 15 mg/kg PO q 24 hrs
Secnidazole